Vitoria, M; Hill, A; Ford, N; Doherty, M; Clayden, P; Venter, F; Ripin, D; Flexner, C; Domanico, PL (2018년 7월 31일). “The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?”. 《AIDS》 32 (12): 1551–61. doi:10.1097/QAD.0000000000001845. PMID29746295. S2CID13674631.
World Health Organization (2019). “Policy brief: update of recommendations on first- and second-line antiretroviral regimens”. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15; License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Vitoria, M; Hill, A; Ford, N; Doherty, M; Clayden, P; Venter, F; Ripin, D; Flexner, C; Domanico, PL (2018년 7월 31일). “The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?”. 《AIDS》 32 (12): 1551–61. doi:10.1097/QAD.0000000000001845. PMID29746295. S2CID13674631.
semanticscholar.org
api.semanticscholar.org
Vitoria, M; Hill, A; Ford, N; Doherty, M; Clayden, P; Venter, F; Ripin, D; Flexner, C; Domanico, PL (2018년 7월 31일). “The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?”. 《AIDS》 32 (12): 1551–61. doi:10.1097/QAD.0000000000001845. PMID29746295. S2CID13674631.
